143 related articles for article (PubMed ID: 29433345)
1. Computed tomography densitometric study of anti-angiogenic effect of regorafenib in colorectal cancer liver metastasis.
Reginelli A; Clemente A; Cardone C; Urraro F; Izzo A; Martinelli E; Troiani T; Ciardiello F; Brunese L; Cappabianca S
Future Oncol; 2018 Dec; 14(28):2905-2913. PubMed ID: 29433345
[TBL] [Abstract][Full Text] [Related]
2. Changes in CT morphology can be an independent response marker for patients receiving regorafenib for colorectal liver metastases: retrospective pilot study.
Ozaki Y; Shindoh J; Gonoi W; Nishioka Y; Kondoh C; Tanabe Y; Matoba S; Kuroyanagi H; Hashimoto M; Takano T
BMC Cancer; 2018 Feb; 18(1):138. PubMed ID: 29402244
[TBL] [Abstract][Full Text] [Related]
3. Clinical Implication of Anti-Angiogenic Effect of Regorafenib in Metastatic Colorectal Cancer.
Lim Y; Han SW; Yoon JH; Lee JM; Lee JM; Paeng JC; Won JK; Kang GH; Jeong SY; Park KJ; Lee KH; Kim JH; Kim TY
PLoS One; 2015; 10(12):e0145004. PubMed ID: 26671465
[TBL] [Abstract][Full Text] [Related]
4. Texture in the monitoring of regorafenib therapy in patients with colorectal liver metastases.
Andersen IR; Thorup K; Andersen MB; Olesen R; Mortensen FV; Nielsen DT; Rasmussen F
Acta Radiol; 2019 Sep; 60(9):1084-1093. PubMed ID: 30612433
[No Abstract] [Full Text] [Related]
5. RECIST and CHOI criteria in the evaluation of tumor response in patients with metastatic colorectal cancer treated with regorafenib, a prospective multicenter study.
Lucidarme O; Wagner M; Gillard P; Kim S; Bachet JB; Rousseau B; Mazard T; Louvet C; Chibaudel B; Cohen R; Garcia-Larnicol ML; Gobert A; Henriques J; André T
Cancer Imaging; 2019 Dec; 19(1):85. PubMed ID: 31818317
[TBL] [Abstract][Full Text] [Related]
6. Imaging and clinical correlates with regorafenib in metastatic colorectal cancer.
Khan K; Cascinu S; Cunningham D; Kim SY; Oki E; Seery T; Shen L; Siena S; Tournigand C; Turhal NS; Hendlisz A
Cancer Treat Rev; 2020 Jun; 86():102020. PubMed ID: 32278232
[TBL] [Abstract][Full Text] [Related]
7. Multicenter Cohort Study to Assess the Association between Changes on Imaging and Outcome after Regorafenib Treatment (KSCC1603).
Oki E; Kawahira M; Kusumoto T; Yuki S; Hatanaka K; Kobayashi Y; Nishie A; Kawanami S; Makiyama A; Saeki H; Sakamoto S; Komatsu Y; Shimokawa M; Mori M; Esaki T
Oncology; 2020; 98(10):719-726. PubMed ID: 32640458
[TBL] [Abstract][Full Text] [Related]
8. Total lesion glycolysis (TLG) as an imaging biomarker in metastatic colorectal cancer patients treated with regorafenib.
Lim Y; Bang JI; Han SW; Paeng JC; Lee KH; Kim JH; Kang GH; Jeong SY; Park KJ; Kim TY
Eur J Nucl Med Mol Imaging; 2017 May; 44(5):757-764. PubMed ID: 27888325
[TBL] [Abstract][Full Text] [Related]
9. Metastatic colorectal cancer responsive to regorafenib for 2 years: a case report.
Yoshino K; Manaka D; Kudo R; Kanai S; Mitsuoka E; Kanto S; Hamasu S; Konishi S; Nishitai R
J Med Case Rep; 2017 Aug; 11(1):227. PubMed ID: 28818109
[TBL] [Abstract][Full Text] [Related]
10. Predictive Value of Early Tumor Shrinkage and Density Reduction of Lung Metastases in Patients With Metastatic Colorectal Cancer Treated With Regorafenib.
Vanwynsberghe H; Verbeke X; Coolen J; Van Cutsem E
Clin Colorectal Cancer; 2017 Dec; 16(4):377-380. PubMed ID: 28454726
[TBL] [Abstract][Full Text] [Related]
11. Dynamic contrast-enhanced computed tomography as a potential biomarker in patients with metastatic colorectal cancer treated with regorafenib.
Andersen IR; Olesen R; Boysen AK; Jensen LH; Mortensen FV; Nielsen DT; Rasmussen F
Acta Radiol; 2019 Jul; 60(7):836-845. PubMed ID: 30348001
[No Abstract] [Full Text] [Related]
12. Antiangiogenic Tyrosine Kinase Inhibitors in Metastatic Colorectal Cancer: Focusing on Regorafenib.
Papadimitriou M; Papadimitriou CA
Anticancer Res; 2021 Feb; 41(2):567-582. PubMed ID: 33517262
[TBL] [Abstract][Full Text] [Related]
13. Survival, safety, and prognostic factors for outcome with Regorafenib in patients with metastatic colorectal cancer refractory to standard therapies: results from a multicenter study (REBECCA) nested within a compassionate use program.
Adenis A; de la Fouchardiere C; Paule B; Burtin P; Tougeron D; Wallet J; Dourthe LM; Etienne PL; Mineur L; Clisant S; Phelip JM; Kramar A; Andre T
BMC Cancer; 2016 Jul; 16():412. PubMed ID: 27389564
[TBL] [Abstract][Full Text] [Related]
14. Liver metastases from colorectal cancer treated with conventional and antiangiogenetic chemotherapy: evaluation with liver computed tomography perfusion and magnetic resonance diffusion-weighted imaging.
Anzidei M; Napoli A; Zaccagna F; Cartocci G; Saba L; Menichini G; Cavallo Marincola B; Marotta E; Di Mare L; Catalano C; Passariello R
J Comput Assist Tomogr; 2011; 35(6):690-6. PubMed ID: 22082538
[TBL] [Abstract][Full Text] [Related]
15. Clinical and molecular assessment of regorafenib monotherapy.
Kakizawa N; Suzuki K; Fukui T; Takayama Y; Ichida K; Muto Y; Hasegawa F; Watanabe F; Kikugawa R; Tsujinaka S; Futsuhara K; Miyakura Y; Noda H; Rikiyama T
Oncol Rep; 2017 Apr; 37(4):2506-2512. PubMed ID: 28259999
[TBL] [Abstract][Full Text] [Related]
16. Response evaluation in patients with colorectal liver metastases: RECIST version 1.1 versus modified CT criteria.
Chung WS; Park MS; Shin SJ; Baek SE; Kim YE; Choi JY; Kim MJ
AJR Am J Roentgenol; 2012 Oct; 199(4):809-15. PubMed ID: 22997372
[TBL] [Abstract][Full Text] [Related]
17. RECIST 1.1, Choi and mChoi criteria in the evaluation of tumor response in patients with metastatic colorectal cancer treated with Regorafenib and anti-PD-1 antibody.
Li L; Xu Y; Yang Y; Ye F; Zhang H; Zhou A; Zhao X
Eur J Radiol; 2021 Aug; 141():109823. PubMed ID: 34146911
[TBL] [Abstract][Full Text] [Related]
18. Regorafenib in the treatment of metastatic colorectal cancer.
de la Fouchardière C
Future Oncol; 2018 Sep; 14(22):2239-2246. PubMed ID: 29569472
[TBL] [Abstract][Full Text] [Related]
19. [Regorafenib approved in Metastatic Colorectal cancer].
André T; Dumont SN
Bull Cancer; 2013 Oct; 100(10):1027-9. PubMed ID: 24047557
[TBL] [Abstract][Full Text] [Related]
20. Chemotherapy rechallenge after regorafenib treatment in metastatic colorectal cancer: still hope after the last hope?
Bertocchi P; Aroldi F; Prochilo T; Meriggi F; Beretta GD; Zaniboni A
J Chemother; 2017 Apr; 29(2):102-105. PubMed ID: 28032528
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
